down arrow

Quince Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US22053A1079
USD
3.60
0.22 (6.51%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.523.72

52 Week

0.723.73
Valuation
Technical
Day's Volume

CASH

2.16 M

Shareholding (Mar 2025)

FII

0.39%

Held by 8 FIIs

DII

94.87%

Held by 5 DIIs

Promoter

0.43%

How big is Quince Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Quince Therapeutics, Inc. has a market capitalization of 61.84 million, with net sales of 0.00 million and a net profit of -60.71 million over the last four quarters. The company reported shareholder's funds of 30.15 million and total assets of 126.15 million as of Dec 24.

Market Cap: As of Jun 18, Quince Therapeutics, Inc. has a market capitalization of 61.84 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Quince Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -60.71 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 30.15 million and total assets of 126.15 million.

Read More

What does Quince Therapeutics, Inc. do?

22-Jun-2025

Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for Alzheimer’s and other degenerative diseases. As of March 2025, it has a market cap of $61.84 million and reported a net profit loss of $15 million.

Overview: <BR>Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on providing disease-modifying therapeutics for Alzheimer’s and other degenerative diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 61.84 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.87 <BR>Return on Equity: -206.93% <BR>Price to Book: 3.33<BR><BR>Contact Details: <BR>Address: 269 E Grand Ave, SOUTH SAN FRANCISCO CA: 94080-4804 <BR>Tel: 1 415 9105717 <BR>Fax: 1 302 6555049 <BR>Website: https://www.cortexyme.com/

Read More

Who are in the management team of Quince Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Quince Therapeutics, Inc. includes Ms. Casey Lynch (Chairman, CEO, Co-Founder), Mr. Stephen Dominy (Co-Founder, Chief Scientific Officer), and Dr. Una Ryan (Lead Independent Director), along with several independent directors.

As of March 2022, the management team of Quince Therapeutics, Inc. includes several key individuals. Ms. Casey Lynch serves as the Chairman of the Board, President, Chief Executive Officer, and is a Co-Founder of the company. Mr. Stephen Dominy is also a Co-Founder and holds the position of Chief Scientific Officer and Director. Additionally, Dr. Una Ryan is the Lead Independent Director. The board includes several independent directors: Mr. David Lamond, Dr. Margaret Mcloughlin, Mr. Christopher Senner, and Mr. Kevin Young.<BR><BR>In summary, as of March 2022, Quince Therapeutics, Inc. is led by a team that includes Ms. Casey Lynch, Mr. Stephen Dominy, and Dr. Una Ryan, along with several independent directors.

Read More

Is Quince Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Quince Therapeutics, Inc. has a mildly bullish trend supported by daily moving averages and Bollinger Bands, despite a mildly bearish weekly MACD, with a strong 1-year return of 119.05% compared to the S&P 500's 17.14%, but a significant 5-year underperformance of -97.19% versus the S&P's 96.61%.

As of 21 August 2025, the technical trend for Quince Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages and a bullish outlook from Bollinger Bands and KST indicators. However, the weekly MACD is mildly bearish, indicating some caution. The stock has shown a strong 1-year return of 119.05%, significantly outperforming the S&P 500's 17.14%, but has underperformed over longer periods, particularly with a 5-year return of -97.19% compared to the S&P's 96.61%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 84 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.50

stock-summary
Return on Equity

-342.25%

stock-summary
Price to Book

7.19

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-16 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
123.6%
0%
123.6%
6 Months
242.86%
0%
242.86%
1 Year
66.67%
0%
66.67%
2 Years
275.0%
0%
275.0%
3 Years
393.15%
0%
393.15%
4 Years
-72.39%
0%
-72.39%
5 Years
-92.49%
0%
-92.49%

Quince Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Quince Therapeutics, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Quince Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages and a bullish outlook from Bollinger Bands and KST indicators. However, the weekly MACD is mildly bearish, indicating some caution. The stock has shown a strong 1-year return of 119.05%, significantly outperforming the S&P 500's 17.14%, but has underperformed over longer periods, particularly with a 5-year return of -97.19% compared to the S&P's 96.61%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
5.46%
EBIT to Interest (avg)
-54.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0
Tax Ratio
0.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.48%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.86
EV to EBIT
-0.91
EV to EBITDA
-0.92
EV to Capital Employed
15.73
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1720.47%
ROE (Latest)
-206.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (4.31%)

Foreign Institutions

Held by 8 Foreign Institutions (0.39%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 42.24% vs -465.31% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.90",
          "val2": "-8.80",
          "chgp": "-12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.40",
          "val2": "-19.80",
          "chgp": "67.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.00",
          "val2": "-27.70",
          "chgp": "42.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -80.89% vs 39.26% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-36.00",
          "val2": "-24.30",
          "chgp": "-48.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-22.80",
          "val2": "-10.40",
          "chgp": "-119.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.80",
          "val2": "-31.40",
          "chgp": "-80.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.90
-8.80
-12.50%
Interest
0.00
0.00
Exceptional Items
-6.40
-19.80
67.68%
Consolidate Net Profit
-16.00
-27.70
42.24%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 42.24% vs -465.31% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-36.00
-24.30
-48.15%
Interest
0.00
0.00
Exceptional Items
-22.80
-10.40
-119.23%
Consolidate Net Profit
-56.80
-31.40
-80.89%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -80.89% vs 39.26% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Quince Therapeutics, Inc. stock-summary
stock-summary
Quince Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.
Company Coordinates stock-summary
Company Details
269 E Grand Ave , SOUTH SAN FRANCISCO CA : 94080-4804
stock-summary
Tel: 1 415 9105717
stock-summary
https://www.cortexyme.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."